摘要
Intravenous drug users(IDUs) have been demonstrated to be highly vulnerable to HIV/AIDS.Nevertheless, the prevalence of Kaposi's sarcoma associated herpesvirus(KSHV), an important co-infected agent with HIV, among this population remained obscure. We conducted a systematic review on the epidemiological features of KSHV among IDUs worldwide. Eligible studies were retrieved from 6 electronic databases(Pub Med, EMBASE, Web of Science, CBM, CNKI and Wanfang).We calculated the pooled prevalence and 95% confidence interval(CI) overall and among subgroups using either random-effects model or fixed-effects model depending on between-study heterogeneity. The potential publication bias was assessed by the Egger's test. A meta-regression analysis was performed to explore the sources of heterogeneity. Finally, twenty-two studies with a total sample of 7881 IDUs were included in the analysis. The pooled prevalence of KSHV was14.71%(95% CI 11.12%–19.46%) among IDUs. Specifically, KSHV prevalence was 10.86%(95% CI6.95%–16.96%) in HIV-negative IDUs, and 13.56%(95% CI 10.57%–17.38%) in HIV-positive IDUs.Moreover, prevalence among IDUs from the three continents involved in the current study was similar:16.10%(95%CI 7.73%–33.54%) in Asia; 14.22%(95%CI 8.96%–22.57%) in Europe and 14.06%(95%CI11.38%–17.37%) in America. Globally, IDUs are at higher risk of the KSHV infection when compared with the general population, regardless of geographical region or HIV-infection status.
Intravenous drug users（IDUs） have been demonstrated to be highly vulnerable to HIV/AIDS.Nevertheless, the prevalence of Kaposi＇s sarcoma associated herpesvirus（KSHV）, an important co-infected agent with HIV, among this population remained obscure. We conducted a systematic review on the epidemiological features of KSHV among IDUs worldwide. Eligible studies were retrieved from 6 electronic databases（Pub Med, EMBASE, Web of Science, CBM, CNKI and Wanfang）.We calculated the pooled prevalence and 95% confidence interval（CI） overall and among subgroups using either random-effects model or fixed-effects model depending on between-study heterogeneity. The potential publication bias was assessed by the Egger＇s test. A meta-regression analysis was performed to explore the sources of heterogeneity. Finally, twenty-two studies with a total sample of 7881 IDUs were included in the analysis. The pooled prevalence of KSHV was14.71%（95% CI 11.12%–19.46%） among IDUs. Specifically, KSHV prevalence was 10.86%（95% CI6.95%–16.96%） in HIV-negative IDUs, and 13.56%（95% CI 10.57%–17.38%） in HIV-positive IDUs.Moreover, prevalence among IDUs from the three continents involved in the current study was similar：16.10%（95%CI 7.73%–33.54%） in Asia; 14.22%（95%CI 8.96%–22.57%） in Europe and 14.06%（95%CI11.38%–17.37%） in America. Globally, IDUs are at higher risk of the KSHV infection when compared with the general population, regardless of geographical region or HIV-infection status.
基金
supported by the Natural Science Foundation of Shanghai (17ZR1401400)
the Natural Science Foundation of China (grant no. 81772170, U603117)
the Doctoral Fund of Ministry of Education of China (Grant No. 20120071120050)
